Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Jan 30, 2025
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-01-28+163,000→ 163,000 totalExercise: $8.04Exp: 2035-01-28→ Common Stock (163,000 underlying)
Footnotes (1)
- [F1]The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.